[DOI] [PubMed] [Google Scholar] 157.Yamada Y., Kusakari Y., Akaoka M., Watanabe M., Tanihata J., Nishioka N., Bochimoto H., Akaike T., Tachibana T., Minamisawa S
your favorite readers and sunglasses paired together in one stylish piece
Despite these challenges, scientific findings in recent years are beginning for the first time to offer a provisional unified field theory of the disease
CrossRef GLP1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, BoYeon Kim, Chang Won Jeong, DaeYeon Kim, Hang A Park, MinHo Kim, Seong Hwan Kim, WonWoo Seo, Woo Jin Kim, Young Sung Suh, Ra Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis Ejike Daniel Eze, Leopold Ntakirutimana, Swase Dominic Terkimbi, Muluken Walle, Abdullahi Hussein Umar, Diresibachew Haile Wondimu, Makinde Vincent Olubiyi, Onyinye Cynthia Okeke, Olufunke Onaadepo, Jimoh Abdulazeez, David Chibuike Ikwuka, Elemi John Ani, Frontiers in Oncology.2026;[Epub] CrossRef GLP1 receptor agonists and the risk for cancer: A metaanalysis of randomized controlled trials Giovanni Antonio Silverii, Christian Marinelli, Costanza Bettarini, Gloria Giovanna Del Vescovo, Matteo Monami, Edoardo Mannucci Diabetes, Obesity and Metabolism.2025
